MedTrace Logo

Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

NCT03854149 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2023-06-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)

Conditions

  • Congenital Heart Disease
  • Atrial Arrhythmia
  • Thromboembolism
  • Anticoagulants Causing Adverse Effects in Therapeutic Use

Sponsors & Collaborators

  • Onassis Cardiac Surgery Centre

    collaborator OTHER

  • Attikon Hospital

    collaborator OTHER

  • MITERA Children's Hospital

    collaborator UNKNOWN

  • AHEPA University Hospital

    lead OTHER

Principal Investigators

  • Georgios Giannakoulas, MD, PhD · AHEPA University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2023-04-30
Completion
2023-05-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03854149 on ClinicalTrials.gov